Artificial sweetener erythritol in STEVIA and cardiovascular event risk? major adverse cardiovascular events (MACE; includes death, nonfatal myocardial infarction, stroke) atherothrombotic disease

atherothrombotic disease risk; (adjusted hazard ratio (95% confidence interval), 1.80 (1.18–2.77) and 2.21 (1.20–4.07), respectively); erythritol enhanced platelet reactivity in vitro and thrombosis

https://www.nature.com/articles/s41591-023-02223-9.epdf?sharing_token=OPTyazxQdZdXsHvnVfy71dRgN0jAjWel9jnR3ZoTv0MTnVt_Yzm2YDkmKtSZJOysYZlROr0ymfAdj9yPHH8bMbP0djhtBJSsEWwB14X1uRmRIkjrCWE10oC-1WmhkYkIvDc2nPleIgMHxf1mT2nI4RRiBKE3TfZCXKPiH90CvmCYAZlu2xzi6S713Ta4VwBol3byuUKfPpnAsNZCFFMnxcxMXqVAmslNo7xvPzbz02c%3D&tracking_referrer=edition.cnn.com

‘In initial untargeted metabolomics studies in patients undergoing cardiac risk assessment (n = 1,157; discovery cohort, NCT00590200), circulating levels of multiple polyol sweeteners, especially erythritol, were associated with incident (3 year) risk for major adverse cardiovascular events (MACE; includes death or nonfatal myocardial infarction or stroke).

Alexander COVID News-Dr. Paul Elias Alexander’s Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Subsequent targeted metabolomics analyses in independent US (n = 2,149, NCT00590200) and European (n = 833, DRKS00020915) validation cohorts of stable patients undergoing elective cardiac evaluation confirmed this association (fourth versus first quartile adjusted hazard ratio (95% confidence interval), 1.80 (1.18–2.77) and 2.21 (1.20–4.07), respectively). At physiological levels, erythritol enhanced platelet reactivity in vitro and thrombosis formation in vivo.
Finally, in a prospective pilot intervention study (NCT04731363), erythritol ingestion in healthy volunteers (n = 8) induced marked and sustained (>2 d) increases in plasma erythritol levels well above thresholds associated with heightened platelet reactivity and thrombosis potential in in vitro and in vivo studies…
findings reveal that erythritol is both associated with incident MACE risk and fosters enhanced thrombosis. Studies assessing the long-term safety of erythritol are warranted.’

Alexander COVID News-Dr. Paul Elias Alexander’s Newsletter is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Go to Dr Alexancer on Substack
Author: Dr. Paul Alexander